Inclusion Criteria:

- Histologically confirmed metastatic or recurrent gastric cancer with prior treatment
for advanced disease.

- Patients who have received 1cycle cancer therapy (radiotherapy, chemotherapy or
chemoradiotherapy) given > 4 weeks prior to the beginning of study therapy

- At least one measurable lesion according to the RECIST criteria. Minimum indicator
lesion size: > 10 mm measured by spiral CT or >20mm measured by conventional
techniques(Except for Phase I setting).

- Patients aged between 20 and 75 years, inclusive, at the time of acquisition of
informed consent

- Patients with performance status(ECOG) 0 to 2

- Abnormal hematologic values (WBC ≥ 3.5 x 109/L, Hemoglobin ≥ 9.0g/dl, platelet count
≥ 100 x 109/L)

- Serum cleatinine ≤ 1.5mg/dl

- Serum bilirubin ≤ 1.5mg/dl. ALT, AST ≤ 2.0 x upper normal limit (or ≤ 3 x upper
normal limit in the case of liver metastases)

- Normal ECG

- Life expectancy ≥ 3 months

- Patients who have given written informed consent to participate in this study

Exclusion Criteria:

- Patients with active multiple cancers; or even if the multiple cancers are
metachronous, have a disease-free period of less than 5 years (but excluding cancer
in situ and skin cancer) (Except for Phase I setting)

- Serious, uncontrolled, concurrent infection(s) or illness(es)

- Patients with no serious concurrent complications (such as heart disease, Intestinal
pneumonia)

- Patients with Liver cirrhosis

- Patients with fresh hemorrhage from the gastrointestinal tract

- Patients with poorly controlled diabetes or are treated by continuous use of insulin

- Patients with concurrent psychiatric disease or psychotic symptoms, and judged to
have difficulties participating in the study

- Patients with retention of body fluid(pleural effusion, ascites, pericardial
effusion) necessitating treatment

- Patients with diarrhea (watery stool)

- Patients with infection, intestinal palsy or intestinal occlusion

- Patients with brain metastasis

- Patients with Gilbert syndrome

- Patients who have experienced serious drug allergy in the past

- Patients who are pregnant and lactating or hope to become pregnant during the study
period

- Patients with prior Taxan (Paclitaxel, Docetaxel) or CPT-11 treatment

- Patients with neuropathy ≥ grade 2

- Others, patients judged by the investigator or subinvestigator to be inappropriate as
subject